Literature DB >> 25843679

Targeting ion channels for cancer therapy by repurposing the approved drugs.

Vijay Pralhad Kale1, Shantu G Amin1, Manoj K Pandey2.   

Abstract

Ion channels have been shown to be involved in oncogenesis and efforts are being poured in to target the ion channels. There are many clinically approved drugs with ion channels as "off" targets. The question is, can these drugs be repurposed to inhibit ion channels for cancer treatment? Repurposing of drugs will not only save investors' money but also result in safer drugs for cancer patients. Advanced bioinformatics techniques and availability of a plethora of open access data on FDA approved drugs for various indications and omics data of large number of cancer types give a ray of hope to look for possibility of repurposing those drugs for cancer treatment. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ca++channels; Cancer; Drug repurpose; Ion channels; K+channels

Mesh:

Substances:

Year:  2015        PMID: 25843679     DOI: 10.1016/j.bbamem.2015.03.034

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

1.  [Calcium channel blocker diltizem transiently inhibits migration and up-regulates metadherin expression in hepatocellular carcinoma cells in vitro].

Authors:  Rui Guo; Xueyuan Jin; Yi Tian; Xiaozhong Huang; Zongfang Li; Jun Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

2.  Repurposing L-Menthol for Systems Medicine and Cancer Therapeutics? L-Menthol Induces Apoptosis through Caspase 10 and by Suppressing HSP90.

Authors:  Uzma Faridi; Sunita S Dhawan; Shaifali Pal; Sanchita Gupta; Ashutosh K Shukla; Mahendra P Darokar; Ashok Sharma; Ajit K Shasany
Journal:  OMICS       Date:  2016-01

3.  Na(+) Micro-Current Value Detection as a New Modality for Identification of Benign and Malignant Disease in Surgery.

Authors:  Xu-Feng Zhang; Zhi-Da Long; Xue-Min Liu; Feng Ma; Qiang Li; Yi Lv
Journal:  Sci Rep       Date:  2016-04-22       Impact factor: 4.379

Review 4.  Mouse models of colorectal cancer as preclinical models.

Authors:  Rebecca E McIntyre; Simon J A Buczacki; Mark J Arends; David J Adams
Journal:  Bioessays       Date:  2015-06-26       Impact factor: 4.345

5.  A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase.

Authors:  Aldo Segura-Cabrera; Reshmi Tripathi; Xiaoyi Zhang; Lin Gui; Tsui-Fen Chou; Kakajan Komurov
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

Review 6.  Targeting calcium signaling in cancer therapy.

Authors:  Chaochu Cui; Robert Merritt; Liwu Fu; Zui Pan
Journal:  Acta Pharm Sin B       Date:  2016-12-13       Impact factor: 11.413

7.  Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations.

Authors:  Ana Correia; Dany Silva; Alexandra Correia; Manuel Vilanova; Fátima Gärtner; Nuno Vale
Journal:  Biomolecules       Date:  2018-12-14

8.  Discovery of NKCC1 as a potential therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis.

Authors:  Yaya Zhou; Wei Sun; Ning Chen; Chen Xu; Xinxin Wang; Kun Dong; Binxue Zhang; Jian Zhang; Ning Hao; Aihua Sun; Handong Wei; Fuchu He; Ying Jiang
Journal:  Oncotarget       Date:  2017-08-12

9.  Pharmacological characterization of crotamine effects on mice hind limb paralysis employing both ex vivo and in vivo assays: Insights into the involvement of voltage-gated ion channels in the crotamine action on skeletal muscles.

Authors:  Sunamita de Carvalho Lima; Lucas de Carvalho Porta; Álvaro da Costa Lima; Joana D'Arc Campeiro; Ywlliane Meurer; Nathália Bernardes Teixeira; Thiago Duarte; Eduardo Brandt Oliveira; Gisele Picolo; Rosely Oliveira Godinho; Regina Helena Silva; Mirian Akemi Furuie Hayashi
Journal:  PLoS Negl Trop Dis       Date:  2018-08-06

Review 10.  Calcium Permeable Channels in Cancer Hallmarks.

Authors:  Sendoa Tajada; Carlos Villalobos
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.